https://www.selleckchem.com/pr....oducts/lenalidomide-
43%) in IL17i new-users, 11 (0.05%) in apremilast new-users and 49 (0.48%) in etanercept new-users. Most IBD cases occurred after 6 months of exposure (82%, 55% and 76% respectively). After propensity score weighting, the risk of IBD was significantly greater with IL17i than apremilast (HR 3.8, 95%CI 2.1-6.8). No difference was observed between IL17i and etanercept new-users (HR 0.8, 95%CI 0.5-1.2). Compared with patients initiating etanercept that displayed the same severity of the underlying disease, IL17i new-users did not
처럼
논평
공유하다
